Browse by Audience
Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine.
Learn More >To determine the efficacy of acceptance and mindfulness-based interventions on migraine disability, medication use, and attack frequency.
Learn More >Central sensitisation is an important mechanism in migraine chronification. It is presumed to occur in second and third order neurons sequentially, resulting in an analogous spatial distribution of cutaneous allodynia […]
Learn More >The present study examined the extent to which emotional experience and emotional competence (EC) change in people with chronic pain during interdisciplinary multimodal pain treatment (IMPT).
Learn More >Chronic pain (pain lasting three months or more) is an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Common types (excluding headache) include back pain, fibromyalgia, […]
Learn More >Several preclinical and clinical studies indicate that exposure to acute stress may decrease pain perception and increases pain tolerance. This phenomenon is called stress-induced analgesia (SIA). A variety of neurotransmitters, […]
Learn More >Pain in early life may impact on development and risk of chronic pain. We developed an optogenetic Cre/loxP mouse model of “early-life-pain” (ELP) using mice with transgenic expression of channelrhodopsin-2 […]
Learn More >Ten chronic overlapping pain conditions are currently recognized by the National Institutes of Health Pain Consortium (e.g., irritable bowel syndrome, chronic migraine headache, and chronic low back pain). These conditions […]
Learn More >Data tracking is a common feature of pain e-health applications, however, viewing visualizations of this data has not been investigated for its potential as an intervention itself. We conducted a […]
Learn More >